Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  AbbVie Inc.    ABBV

ABBVIE INC.

(ABBV)
  Report
Real-time Estimate Quote. Real-time Estimate Cboe BZX - 10/27 02:57:52 pm
83.42 USD   -0.60%
10:15aABBVIE INC. : quaterly earnings release
10/19ABBVIE : Seeks U.S., European OK of Rinvoq in Eczema
DJ
10/19ABBVIE : VENCLEXTA Receives FDA Full Approval for Acute Myeloid Leukemia
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

All news about ABBVIE INC.
10:15aABBVIE INC. : quaterly earnings release
10/19ABBVIE : Seeks U.S., European OK of Rinvoq in Eczema
DJ
10/19ABBVIE : VENCLEXTA Receives FDA Full Approval for Acute Myeloid Leukemia
AQ
10/19ABBVIE : Submits Regulatory Applications to FDA and EMA for RINVOQ™ (upada..
PR
10/19ABBVIE INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
10/19ABBVIE : Announces Commencement of Registered Exchange Offers
PR
10/16NEWS HIGHLIGHTS : Top Company News of the Day
DJ
10/16NEWS HIGHLIGHTS : Top Company News of the Day
DJ
10/16NIH to Study Three Drugs in Treatment of Covid-19 Patients
DJ
10/14ABBVIE INC. : Ex-dividend day for
FA
More news
Financials (USD)
Sales 2020 45 374 M - -
Net income 2020 8 566 M - -
Net Debt 2020 74 016 M - -
P/E ratio 2020 16,5x
Yield 2020 5,88%
Capitalization 148 B 148 B -
EV / Sales 2020 4,90x
EV / Sales 2021 3,96x
Nbr of Employees 47 000
Free-Float 98,5%
Chart ABBVIE INC.
Duration : Period :
AbbVie Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABBVIE INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 20
Average target price 109,25 $
Last Close Price 83,92 $
Spread / Highest target 51,3%
Spread / Average Target 30,2%
Spread / Lowest Target 14,4%
EPS Revisions
Managers
NameTitle
Richard A. Gonzalez Chairman & Chief Executive Officer
Michael E. Severino Vice Chairman & President
Azita Saleki-Gerhardt Executive Vice President-Operations
Robert A. Michael Chief Financial Officer & Executive Vice President
Thomas J. Hudson Chief Scientific Officer, Senior VP-R&D
Sector and Competitors
1st jan.Capitalization (M$)
ABBVIE INC.-5.22%148 105
JOHNSON & JOHNSON-1.30%379 007
ROCHE HOLDING AG-4.55%282 543
PFIZER INC.-3.22%210 717
MERCK & CO., INC.-13.32%199 405
NOVARTIS AG-16.94%185 381